Omifred-D Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Omeprazole 20mg, designed to manage gastrointestinal disorders characterized by acid-related symptoms and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric emptying by enhancing gastrointestinal motility and exhibits antiemetic properties by blocking dopamine receptors in the chemoreceptor trigger zone. Omeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, thereby providing symptomatic relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The combination of Domperidone and Omeprazole in Omifred-D Capsule offers a synergistic effect, addressing both delayed gastric emptying and excessive acid production, which are common etiologies in dyspepsia and related disorders. This formulation is indicated for patients experiencing symptoms like heartburn, acid regurgitation, nausea, and vomiting associated with acid peptic diseases. Omifred-D should be administered under medical supervision, considering contraindications such as hypersensitivity to either component, and caution is advised in patients with cardiac arrhythmias or prolonged QT interval. Adherence to prescribed dosage and duration is essential to optimize therapeutic outcomes and minimize potential adverse effects.